For laboratory use only. This product is intended for animal research only and not for use in humans.
VivoTrack 680 is a water soluble NIR cell labeling agent that can label a variety of cell types for applications in inflammation, immunology, and stem cells.
The kit contains 1 vial of VivoTrack 680 containing 0.2mg of the labeling agent formulated in polyethylene glycol and is in dry solid form. The packaged material provides sufficient reagent to label up to 2 x 108 cells.
| Optical Imaging Classification | Fluorescence Imaging |
|---|---|
| Product Brand Name | VivoTrack |
| Quantity in a Package Amount | 1.0 Units |
| Shipping Condition | Blue Ice |
| Unit Size | 1 Kit |
| Wave Length | 680 nm |
Fluorescent dyes have been used for many years to label cells for microscopy studies, and a variety of dyes in the visible fluorescence spectrum are available to label different cellular compartments and organelles. Efficient delivery of the fluorophore to the cell without excessively modifying surface proteins or perturbing cell function is the major biotechnological challenge. In addition, researchers have taken on the challenge of in vivo imaging, focusing on near infrared (NIR) dyes that fluoresce in a spectral region better suited for in vivo imaging due to reduced background and higher tissue penetration.
VivoTrack 680 (Explorer Kit) is a near infrared fluorescent cell labeling agent that intercalates into the plasma membrane of primary cells and cell lines. Cells are brightly labeled and retain excellent viability and function, with the near infrared wavelength of the fluorescence offering optimal in vitro and in vivo detection.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.
